|
Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.〔 〕 While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit.〔 In December 2011, Novartis halted a clinical trial of the drug after discovering increased incidence of nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney impairment.〔Healthzone.ca: (Blood-pressure drug reviewed amid dangerous side effects )〕 As a result, in April 20, 2012: * A new contraindication was added to the product label concerning the use of aliskiren with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) in patients with diabetes because of the risk of kidney impairment, low blood pressure, and high levels of potassium in the blood. * A warning to avoid use of aliskiren with ARBs or ACEIs was also added for patients with moderate to severe kidney impairment (i.e., where glomerular filtration rate is less than 60 ml/min). Aliskiren was co-developed by the Swiss pharmaceutical companies Novartis and Speedel. ==Medical uses== While used for high blood pressure, other better studied medications are typically recommended.〔 ''Prescrire'' has stated that aliskiren is potentially more harmful than beneficial and thus list it as of 2014 as a drug to avoid. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Aliskiren」の詳細全文を読む スポンサード リンク
|